June 22, 2020
The CRIS Board is pleased to announce that Dr Danny Soon has been appointed Chief Executive Office of Consortium for Clinical Research and Innovation Singapore (CRIS), and Executive Director of Singapore Clinical Research Institute (SCRI). He will assume these concurrent positions full-time from 1 Aug 2020 and on a part-time basis during July 2020.
As the first CEO of CRIS, Danny will have the responsibility for building CRIS as the Headquarters (HQ) for its five business units. He will provide strategic direction and oversight to CRIS in partnership with its business units, to ensure that the Consortium achieves its vision and mission to keep Singapore’s clinical research capabilities and innovation at the cutting edge, while maintaining accountability to the Ministry of Health (MOH) and other key stakeholders. Danny will work closely with MOH divisions and stakeholders to ensure effective and efficient translation of policy objectives into implementation.
As ED of SCRI, Danny will be accountable to deliver on SCRI’s mission. SCRI strives to improve patient care as Singapore’s academic research organisation through the design and support of cutting-edge clinical trials and research by working closely with its partners, including leading pharmaceutical, medical devices and biotech organisations, and investigators in the public sector healthcare system.
Danny presently holds the position of Executive Director, Biomedical Research Council (BMRC) in A*STAR. His team in BMRC is responsible for incepting and coordinating efforts and programmes in drug development, precision medicine, medical technology and biomanufacturing. Danny has had long experience in drug development, having been founding CEO of the Experimental Biotherapeutics Centre in A*STAR and previously with Eli Lilly and Company for 15 years, where he was Managing Director and Principal Investigator of the Lilly Singapore pharmacology research centre.
The Consortium for Clinical Research and Innovation Singapore (CRIS), a wholly owned subsidiary of MOH Holdings, has been established in 2020 with the goal of strengthening synergies and promulgating strategies for national-level clinical research and translation programmes that are under the stewardship of the Ministry of Health (MOH).
CRIS has been formed by repurposing the former Singapore Clinical Research Institute Pte Ltd and brings together the following five entities as business units under a common management and governance structure:
Each business unit will continue to be accountable to their respective Board Oversight Committees for deliverables. The CRIS Board and CRIS HQ will address corporate governance and support matters, and optimise synergies in operations and research efforts across these entities.
SINGAPORE - The development of mRNA-based cancer vaccines in Singapore is being funded by the Ministry of Health (MOH), as part of its support for “competitive cancer research projects” here, said Senior Minister of State for Health Janil Puthucheary.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system